JLPC(SH:600513) Zhi Tong Cai Jing·2025-08-04 09:28Core Viewpoint - The company, Lianhuan Pharmaceutical, announced that its subsidiary, Xinxiang Changle Pharmaceutical, received approval from the National Medical Products Administration for the supplement application of Lincomycin Hydrochloride Injection, indicating successful consistency evaluation of the generic drug [1] Group 1: Company Developments - Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical, has been approved for Lincomycin Hydrochloride Injection, which is a significant milestone for the company [1] - The approved product is a Lincomycin class antibiotic, indicated for respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] Group 2: Market Insights - The sales revenue for Lincomycin Hydrochloride Injection (2ml:0.6g) in domestic sample hospitals is projected to be 10.82 million yuan in 2024 [1]